The Inflation Reduction Act's Medicare Part D out-of-pocket cap of $2,100 improves cancer drug affordability for patients, but its price negotiations strain community oncology practices. Price cuts of 30% to 40% on drugs like ibrutinib reduce practice revenues, while upfront drug costs and delayed reimbursements create severe cash flow burdens. Unintended consequences include rising standalone premiums, which push patients toward Medicare Advantage plans.
Financial strains on community oncology practices
- ▪Lance Ortega, executive director of clinical operations at Texas Oncology, stated that reimbursement varies by payer, causing some drugs to generate small margins, break even, or lose money.
- ▪Medicare price cuts of 30% to 40% on negotiated drugs like ibrutinib are projected to reduce revenue for community oncology practices.
- ▪Although community oncology practices were promised Inflation Reduction Act refunds within 21 to 28 days, practices have little experience with this timeline as of September 2026.
- ▪Community oncology practices face cash flow burdens because they must pay for expensive cancer drugs upfront while reimbursement from payers can take 30 to 120 days.
Improving cancer drug affordability for patients
- ▪The Inflation Reduction Act's Medicare Part D out-of-pocket drug spending cap of $2,100 annually has improved cancer care affordability for Medicare patients as of September 2026.
- ▪A study cited by Vanderbilt University professor Stacie Dusetzina found that approximately one in three patients with a new cancer diagnosis previously did not fill high-priced drug prescriptions.
- ▪The Inflation Reduction Act allows Medicare patients to opt into a "smoothing" payment plan to spread out-of-pocket prescription drug costs through monthly payments.
Rising Medicare Part D premiums
- ▪Vanderbilt University professor Stacie Dusetzina stated that standalone Medicare Part D premium announcements for open enrollment are expected to be high.
- ▪Vanderbilt University professor Stacie Dusetzina stated that lawmakers she has talked to are worried about premiums and whether people can afford coverage.
- ▪The more generous Medicare Part D benefits under the Inflation Reduction Act have led to rising standalone premiums for beneficiaries.
Growth of Medicare Advantage enrollment
- ▪Rising standalone Part D premiums are pushing more Medicare beneficiaries toward Medicare Advantage plans, where prior authorization and step therapy are common.
- ▪Medicare Advantage plans cover more than half of all Medicare beneficiaries, representing 32.8 million enrollees as of August 2024.
- ▪Vanderbilt University professor Stacie Dusetzina expects the share of Medicare beneficiaries enrolled in Medicare Advantage plans to grow.
AARP efforts to expand drug price controls
- ▪The advocacy group AARP is lobbying lawmakers to expand the Inflation Reduction Act's drug price controls if Democrats retake Congress and the White House.
- ▪A report by the advocacy group AARP concluded that expanding Inflation Reduction Act price controls to 10 currently exempt medicines could save Medicare nearly $200 billion between 2029 and 2033.
Debatable claims
- ▪Congress should expand Medicare drug price controls to more medicines
- ▪Medicare drug price negotiations threaten the viability of community oncology practices
- ▪The Medicare Part D cap does more harm than good by raising premiums
Story comments
Loading comments…